I took part in the iCMLf ERSAP Preceptorship Program from 02-29 Aug 2010 at MD Anderson Cancer Center in Houston, USA. The main goal of my visit and taking part in the programme was gain more knowl...
From 1-15 September 2011, I completed a training activity through the iCMLf and its partner, the Max Foundation. The training included the sponsorship of a patient assistance program, giving free a...
I attended meetings organized by the leukemia department in the MD Anderson, e.g. the leukemia rounds every Tuesday and Thursday, discussing about new patients and inpatients. Every week they made ...
Applications for the 2013 program are now open and we still have many countries to reach so please share the information about this preceptorship program with colleagues who may benefit. Completed application forms should be emailed to firstname.lastname@example.org.
This program is designed for clinicians from emerging economic regions with a specific interest in the treatment of CML and a significant CML patient load. The program enhances clinical knowledge and skills in the treatment of CML through preceptorships at internationally renowned CML centres.
Participants are part of the clinical team at the host site for the duration of the preceptorship, undertaking seminars and laboratory work where appropriate. Through this practical application of learning, clinicians attending the preceptorship have the opportunity to develop and enhance clinical knowledge to take back and share with colleagues in their country of origin. The programs are 'no profit' for the specialist CML centres, which donate their staff and resources to facilitate the program. More information about the ERSAP Clinical Preceptorship Program can be found in the program brochure.
About to start its forth year, the ERSAP Clinical Preceptorship Program is having a positive impact in the treatment of CML across emerging economic regions. Feedback from preceptors has confirmed that the goals of the program are being met, indicating improved knowledge and plans to share this with colleagues at home. Preceptors form collaborations with the host centre and many are undertaking further research projects.
The following comments are examples of this feedback:
The iCMLf seeks to improve the resources and knowledge of physicians treating patients with CML in emerging regions. The iCMLf will select up to 30 hematologists for the program whose attendance is expected to provide most benefit in this CML community. Candidates should have a special interest in CML management and be able to demonstrate their ability to apply and disseminate to colleagues knowledge gained from the program.
Through one-on-one tuition and hands-on experience, participants will conclude the program with a practical understanding of the latest information influencing the care of patients with CML. This will include:
• therapies to treat CML; efficacy, toxicity and the management of side effects
• monitoring guidelines
• management of resistance
• role of allograft in CML
• developments in novel therapies, vaccines and drug cessation
The preceptorships are designed as an interactive process with participants steering their own education throughout the program.
Preceptorships will take place at eleven designated international specialist CML centres and last for 3-4 weeks. Host sites include English, French, Italian, Russian and Spanish speaking centres.
Find detailed descriptions of the participating centers here.
Download the documents of the 2013 ERSAP Clinical Preceptorship Program: